QC
AVTX icon

Quadrature Capital’s Avalo Therapeutics AVTX Stock Holding History

Quadrature Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Sell
15,405
-109,790
-88% -$1.74M ﹤0.01% 1221
2026
Q1 		$1.87M Buy
125,195
+72,151
+136% +$1.13M 0.02% 397
2025
Q4 		$963K Sell
53,044
-1,955
-4% -$33K 0.01% 528
2025
Q3 		$696K Buy
54,999
+44,023
+401% +$379K 0.01% 440
2025
Q2 		$54.8K Buy
+10,976
New +$51.3K ﹤0.01% 938

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Quadrature Capital's AVTX Position: Q2 2026 in Review

Quadrature Capital reduced its Avalo Therapeutics (AVTX) stake by 88% in Q2 2026, selling an estimated $1.74M and leaving 15,405 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #1221.

Quadrature Capital first reported a position in AVTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.87M in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Quadrature Capital held 15,405 shares of Avalo Therapeutics worth $285K as of Q2 2026.
  • Quadrature Capital sold 109,790 Avalo Therapeutics shares in Q2 2026, an estimated $1.74M.
  • Avalo Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1221 holding.
  • Quadrature Capital first reported a position in Avalo Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Avalo Therapeutics position peaked at $1.87M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.